Author

Alai Goñi

Observed names: Alai Goñi Ramirez, Alai Goñi Ramírez, Goñi Ramírez, Alai

Observed institution: Onkologikoa

ORCID: 0000-0002-6365-9617

Observed ORCID: 0000-0002-6365-9617

OpenAlex ID: A5080027172

The Urinary Transcriptome as a Source of Biomarkers for Prostate Cancer

2020 · Carla Solé, Ibai Goicoechea, et al. · Cancers · 24

PDF

Mortality and biochemical recurrence after surgery, brachytherapy, or external radiotherapy for localized prostate cancer: a 10-year follow-up cohort study

2022 · José Francisco Suárez, Víctor Zamora, et al. · Scientific Reports · 19

Comparative Effectiveness Research in Localized Prostate Cancer: A 10-Year Follow-Up Cohort Study

2020 · Olatz Garin, José Francisco Suárez, et al. · International Journal of Radiation Oncology*Biology*Physics · 16

Twenty-year Patient-reported Outcomes After Surgery, Radiotherapy, or Brachytherapy for Localized Prostate Cancer

2025 · Víctor Zamora, Olatz Garin, et al. · European Urology Open Science · 1

Evidence in real-world settings for multiple primary malignancies in prostate cancer: Comparison with single primary prostate cancers.

2025 · Alai Goñi, Macarena Sevilla, et al. · Journal of Clinical Oncology · 1

22 Questioning androgen deprivation in prostate brachytherapy monotherapy: ADT Versus no ADT — long-term follow-up

2026 · Alai Goñi Ramirez, Mikel Eguiguren, et al. · Radiotherapy and Oncology

21 Intermediate-Risk Prostate Cancer: Long-Term Outcomes of HDR Brachytherapy Boost Versus LDR Brachytherapy Monotherapy

2026 · Alai Goñi Ramirez, Mikel Eguiguren, et al. · Radiotherapy and Oncology

782 Changes in muscular and adipose compartments during radiotherapy for head and neck cancer

2026 · Ainhoa Díez Arancibia, Carlos Vicente Blanco Garcia, et al. · Radiotherapy and Oncology

PSMA PET Imaging in the Postradiotherapy Setting: Implications for the Diagnosis of Recurrent Prostate Cancer

2026 · Victoria Vera Barragán, Felipe Couñago, et al. · Clinical Genitourinary Cancer

Salvage brachytherapy for local recurrence of prostate cancer. Evaluation of technique and dose fractionation, impact of early diagnosis, and its effect on survival. A multicenter retrospective observational study: RESPRO

2025 · Patricia Willisch, Elena Villafranca, et al. · Brachytherapy

Management of high-risk prostate cancer in Spain: results from a national patterns of care survey

2025 · Victor Duque-Santana, Maria Antonia Gómez-Aparicio, et al. · Clinical & Translational Oncology

2243 Fractal dimension and lacunarity as predictive radiomic features for relapse in pulmonary nodules

2025 · Maria Pagola, Miren Josune Urien, et al. · Radiotherapy and Oncology

141 Long-term outcomes of LDR brachytherapy plus EBRT in prostate cancer: Influence of androgen deprivation therapy on disease progression and toxicity

2025 · Alai Goñi Ramirez, Macarena Sevilla, et al. · Radiotherapy and Oncology

140 20-year outcomes of Low-Dose-Rate versus High-Dose-Rate brachytherapy boost in prostate cancer: A comparative study

2025 · Alai Goñi Ramirez, Macarena Sevilla, et al. · Radiotherapy and Oncology

Economic Evaluation of Traditional Treatments for Localized Prostate Cancer: A 10‐Year Cohort Study

2025 · Víctor Zamora, Guillermo Bosch, et al. · European Journal of Cancer Care

PDF

210 20 years of HDR brachytherapy boost in high-risk prostate cancer patients: long-term outcomes

2024 · Alai Goñi Ramirez, Mikel Larruskain, et al. · Radiotherapy and Oncology

355: Quarter of a century iodine-seed monotherapy: a silver jubilee of clinical triumphs

2024 · Alai Goñi, Belen De Paula, et al. · Radiotherapy and Oncology

243: Evaluation of EMBARK criteria patients. Real-world data on prostate cancer biochemical recurrence.

2024 · Elena Centelles Hidalgo, Antonio Gomez-Caamano, et al. · Radiotherapy and Oncology

1484: Evaluating Local Failure in Lung Cancer Post-SBRT: The Role of SUVmax

2024 · María Pagola, Miren Josune Urien, et al. · Radiotherapy and Oncology

PDF

Works count: 22

Citation count: 81

H-index: 4

I10-index: 4